

# Azienda di produzione farmaceutica di 40 anni fa



**MERGERSCORP**

## Azienda di produzione farmaceutica di 40 anni fa

L'azienda è stata fondata nel distretto indiano del Punjab nel 1982 con l'obiettivo di produrre ingredienti farmaceutici attivi.

L'azienda è una società di produzione di ingredienti farmaceutici attivi (API) che produce materie prime per diverse aziende leader del settore farmaceutico, che utilizzano questi prodotti per la produzione di farmaci.

Fornisce prodotti ad aziende quali Pfizer, Abbott, Cipla, Glenmark, Macleods, Aristo, ecc.

L'offerta dell'azienda spazia dagli antibiotici alle vitamine, dagli anti-coagulanti ai prodotti oftalmici. L'azienda è inoltre sottoposta a controlli da parte di diverse organizzazioni come ISO, ZED e GMP da parte di enti normativi in India e all'estero.

### Ricerca

L'azienda sta lavorando su una tecnologia brevettata per una proteina ricombinante che funziona con una nuova terapia mirata e assicura anche l'assenza di effetti collaterali. Attualmente le operazioni si concentrano su molecole innovative di alto livello.

### Studi

L'azienda sta attualmente conducendo studi sperimentali sulle terapie di ringiovanimento a base di cellule staminali che promettono un futuro di farmaci senza effetti collaterali.

### Biotechologia

L'azienda è impegnata in importanti attività di ricerca biotecnologica nel settore delle proteine terapeutiche umane mirate. Il suo attuale lavoro di ricerca si concentra sulla creazione di un nuovo farmaco che, oltre a curare i pazienti affetti da asma e allergie, possa agire anche sulla mastocitosi e sulla leucemia basofila.

### Squadra

Il team è composto da 100 persone illuminate, chimici, farmacisti, biotecnologi, controllori di qualità, esperti di ricerca e sviluppo, personale di magazzino.

**Mercato:** 65% India / 35% Resto del mondo / Europa

**Prodotti:** 25 Prodotti OEM / Materia prima di principi attivi farmaceutici

**I più venduti:** Antibiotici

**Standard:** ISO9001, Standard UE (No FDA)

**Tasso di crescita:** 20%+ all'anno

**Dimensione:** 100+ dipendenti

**Gestione:** Background da ingegnere chimico

**Finanziario:** 25 milioni di dollari di fatturato / 3 milioni di dollari di EBITDA

### TARGET PRICE

\$40,000,000

### GROSS REVENUE

\$25,000,000

### EBITDA

\$3,000,000

### BUSINESS TYPE

Farmaceutico

### ESTABLISHED

1989

### SUPPORT & TRAINING

12 mesi

### COUNTRY

India

### BUSINESS ID

L#20210013

Clienti:



**Abbott**



**glenmark**  
A new way for a new world

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

## MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

**MERGERSCORP**

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)